Sutro Biopharma Secures $36,500,000 Series C Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4abc323e-00ef-4dcc-abe9-bd2582d6744e&Preview=1 -
Date
11/17/2010 -
Company Name
Sutro Biopharma -
Mailing Address
310 Utah Ave South San Francisco, CA 94080 -
Company Description
Sutro Biopharma, Inc. is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease.
This commercially scalable technology overcomes important limitations associated with mammalian, yeast, and bacterial systems and allows for faster screening and selection of product candidates without the need to develop cell lines. -
Website
http://www.sutrobio.com -
Transaction Type
Venture Equity -
Transaction Amount
$36,500,000 -
Transaction Round
Series C -
Proceeds Purposes
This financing will support the company’s ongoing development of novel biotherapeutics with superior pharmaceutical properties and advance the company’s biochemical protein synthesis platform to meet current Good Manufacturing Practice (cGMP) standards. -
M&A Terms
-
Venture Investor
Skyline Ventures -
Venture Investor
Lilly Ventures -
Venture Investor
Amgen Ventures -
Venture Investor
SV Life Sciences -
Venture Investor
Alta Partners
